Grant

Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)

Active

$568.2K Funding

7 People

External

Brianna Denton
(CD)
Cancer Center Division﹒Research Compliance Manager I
Diana Dawson
(CD)
Cancer Center Division﹒Research Compliance Administrator II
Umbreen Rozell
Co-Investigator (COI)
Medicine﹒Assistant Clinical Professor, Medicine - (Clinical Series Track)
Aaron Scott
Principal Investigator (PI)
Medicine﹒Associate Professor, Medicine - (Clinical Scholar Track)
Hina Arif Tiwari
Co-Investigator (COI)
Pathology and Lab Medicine﹒Professor
Rachna Shroff
Co-Investigator (COI)
Medicine﹒Professor
Gustavo Cornejo
(CD)
Az Health Sciences Division﹒Research Compliance Administrator III